

# Steven H Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9293459/publications.pdf>

Version: 2024-02-01

225  
papers

9,062  
citations

47004

47  
h-index

58576

82  
g-index

230  
all docs

230  
docs citations

230  
times ranked

10213  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. <i>Cell Research</i> , 2020, 30, 146-162.	12.0	616
2	Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.	27.8	379
3	Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. <i>Frontiers in Pharmacology</i> , 2018, 9, 185.	3.5	277
4	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , 2021, 9, 467-475.	10.7	277
5	Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2960-2974.	1.6	258
6	Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1078-1085.	0.8	230
7	A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 42-51.	4.4	218
8	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. <i>Nature Cancer</i> , 2020, 1, 176-183.	13.2	201
9	Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 128-135.	0.8	184
10	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. <i>Nature Metabolism</i> , 2019, 1, 431-444.	11.9	158
11	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	1.6	158
12	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. <i>Lancet Oncology</i> , 2021, 22, 1448-1457.	10.7	154
13	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 2104-2115.	8.2	152
14	Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. <i>Gastroenterology</i> , 2020, 158, 494-505.e6.	1.3	147
15	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. <i>Journal of Clinical Oncology</i> , 2020, 38, e001001.		143
16	Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 117, 73-79.	2.0	135
17	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	12.8	120
18	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, e172032.	7.1	119

#	ARTICLE	IF	CITATIONS
19	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival. The University of Texas MD Anderson Cancer Center experience. <i>Cancer</i> , 2017, 123, 4106-4113.	4.1	118
20	Spatial mapping of the biologic effectiveness of scanned particle beams: towards biologically optimized particle therapy. <i>Scientific Reports</i> , 2015, 5, 9850.	3.3	117
21	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. <i>Radiotherapy and Oncology</i> , 2018, 128, 154-160.	0.6	109
22	Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 163-170.	0.6	107
23	Proton Beam Therapy and Concurrent Chemotherapy for Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, e345-e351.	0.8	104
24	The Rise of Radiomics and Implications for Oncologic Management. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	104
25	The Incremental Value of Subjective and Quantitative Assessment of <sup>18</sup> F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 691-700.	5.0	99
26	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	1.1	97
27	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1267-1279.	3.4	92
28	Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 376-381.	0.6	81
29	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 667-676.	0.8	79
30	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 362-371.	0.8	78
31	Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. <i>Neuro-Oncology</i> , 2021, 23, 284-294.	1.2	78
32	Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. <i>Cancer</i> , 2016, 122, 917-928.	4.1	75
33	Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. <i>Cancer</i> , 2011, 117, 4823-4833.	4.1	72
34	Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. <i>Radiotherapy and Oncology</i> , 2017, 125, 48-54.	0.6	69
35	Lymphocyte-Sparing Effect of Proton Therapy in Patients with Esophageal Cancer Treated with Definitive Chemoradiation. <i>International Journal of Particle Therapy</i> , 2017, 4, 23-32.	1.8	69
36	Ultra high dose rate (35% Gy/sec) radiation does not spare the normal tissue in cardiac and splenic models of lymphopenia and gastrointestinal syndrome. <i>Scientific Reports</i> , 2019, 9, 17180.	3.3	66

#	ARTICLE	IF	CITATIONS
37	Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer. <i>Annals of Surgery</i> , 2019, 269, 663-670.	4.2	65
38	Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 488-497.	0.8	64
39	Motion-robust intensity-modulated proton therapy for distal esophageal cancer. <i>Medical Physics</i> , 2016, 43, 1111-1118.	3.0	63
40	PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. <i>Nature Communications</i> , 2016, 7, 10633.	12.8	63
41	Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1682-1690.	1.1	63
42	Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling. <i>Nature Communications</i> , 2019, 10, 4363.	12.8	61
43	New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development. <i>Cancer Prevention Research</i> , 2015, 8, 1027-1035.	1.5	60
44	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.6	58
45	High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 584-590.	0.6	58
46	Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 644-664.	1.4	56
47	Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 499-505.	0.6	56
48	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	6.3	56
49	Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 558-563.	0.8	55
50	The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 146, 180-186.	0.6	54
51	The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 936-948.	0.8	53
52	ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, .	11.9	52
53	The relationship of lymphocyte recovery and prognosis of esophageal cancer patients with severe radiation-induced lymphopenia after chemoradiation therapy. <i>Radiotherapy and Oncology</i> , 2019, 133, 9-15.	0.6	50
54	Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1064-1071.	1.3	48

#	ARTICLE	IF	CITATIONS
55	The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 124, 318-324.	0.6	47
56	Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 998-1009.	0.8	46
57	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. <i>BMC Genomics</i> , 2014, 15, 1079.	2.8	45
58	Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1152-1160.	1.1	44
59	Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2696-2715.	2.8	43
60	Outcomes of Stereotactic Body Radiotherapy for T1-T2N0 Small Cell Carcinoma According to Addition of Chemotherapy and Prophylactic Cranial Irradiation: A Multicenter Analysis. <i>Clinical Lung Cancer</i> , 2017, 18, 675-681.e1.	2.6	42
61	Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 117-123.	2.6	42
62	Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. <i>Practical Radiation Oncology</i> , 2020, 10, e16-e26.	2.1	42
63	Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. <i>Science Advances</i> , 2020, 6, eaaz6162.	10.3	42
64	Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. <i>JAMA Network Open</i> , 2020, 3, e201929.	5.9	42
65	Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 811-819.	0.8	41
66	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 686-693.	6.3	40
67	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 101-109.	1.1	38
68	A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 965-973.	1.1	35
69	Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5744-5756.	7.0	35
70	Breathing New Life Into Hypoxia-Targeted Therapies for Non-small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1-2.	6.3	34
71	Multimodal Imaging of Pathologic Response to Chemoradiation in Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 996-1001.	0.8	34
72	Reirradiation of thoracic cancers with intensity modulated proton therapy. <i>Practical Radiation Oncology</i> , 2018, 8, 58-65.	2.1	34

#	ARTICLE	IF	CITATIONS
73	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
74	Bayesian Group Sequential Clinical Trial Design Using Total Toxicity Burden and Progression-Free Survival. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 273-297.	1.0	32
75	Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. Annals of Surgery, 2018, 268, 289-295.	4.2	32
76	Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Nonâ€“Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. Clinical Lung Cancer, 2015, 16, 156-163.	2.6	31
77	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 341-350.	7.0	31
78	Alternative Multidisciplinary Management Options for Locally Advanced NSCLC During the Coronavirus Disease 2019 Global Pandemic. Journal of Thoracic Oncology, 2020, 15, 1137-1146.	1.1	31
79	The emerging field of radiomics in esophageal cancer: current evidence and future potential. Translational Cancer Research, 2016, 5, 410-423.	1.0	31
80	The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 71-80.	6.4	30
81	Advances in radiotherapy for esophageal cancer. Annals of Translational Medicine, 2018, 6, 79-79.	1.7	30
82	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. Journal of Cardiovascular Imaging, 2019, 27, 268.	0.7	30
83	A Multi-institutional Analysis of Trimodality Therapy for Esophageal Cancer in Elderly Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 820-828.	0.8	28
84	Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience. Advances in Radiation Oncology, 2017, 2, 301-307.	1.2	28
85	NTCP model for postoperative complications and one-year mortality after trimodality treatment in oesophageal cancer. Radiotherapy and Oncology, 2019, 141, 33-40.	0.6	28
86	Comparing Proton Beam to Intensity Modulated Radiation Therapy Planning in Esophageal Cancer. International Journal of Particle Therapy, 2015, 1, 866-877.	1.8	28
87	Prospective Study of Patient-Reported Symptom Burden in Patients With Nonâ€“Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management, 2016, 51, 832-838.	1.2	27
88	Modern Radiotherapy and Risk of Cardiotoxicity. Chemotherapy, 2020, 65, 65-76.	1.6	27
89	Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiotherapy and Oncology, 2014, 113, 379-384.	0.6	26
90	Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients. Journal of Cancer, 2017, 8, 3242-3250.	2.5	26

#	ARTICLE	IF	CITATIONS
91	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. <i>Clinical Lung Cancer</i> , 2021, 22, e451-e465.	2.6	26
92	Patterns of failure and clinical outcomes of definitive radiotherapy for cervical esophageal cancer. <i>Oncotarget</i> , 2017, 8, 21852-21860.	1.8	26
93	Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. <i>Clinical Cancer Research</i> , 2016, 22, 5876-5886.	7.0	25
94	Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 635-646.	2.4	25
95	Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. <i>Radiotherapy and Oncology</i> , 2021, 154, 187-193.	0.6	25
96	Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 17, 17-23.	1.7	24
97	Cancer associated macrophage-like cells and prognosis of esophageal cancer after chemoradiation therapy. <i>Journal of Translational Medicine</i> , 2020, 18, 413.	4.4	24
98	Esophageal cancer: diagnosis and management. <i>Chinese Journal of Cancer</i> , 2010, 29, 843-854.	4.9	24
99	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 269-277.	1.1	23
100	Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1598-1607.	1.5	22
101	Simple oligonucleotide-based multiplexing of single-cell chromatin accessibility. <i>Molecular Cell</i> , 2021, 81, 4319-4332.e10.	9.7	22
102	Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69.	3.7	21
103	Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base. <i>Annals of Surgical Oncology</i> , 2018, 25, 1245-1253.	1.5	20
104	Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1742-1751.	6.4	20
105	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 252-257.	0.6	20
106	Plasmonic nano-aperture label-free imaging (PANORAMA). <i>Nature Communications</i> , 2020, 11, 5805.	12.8	19
107	<sup>18</sup> F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1756-1763.	5.0	18
108	Association of Treatment at High-Volume Facilities With Survival in Patients Receiving Chemoradiotherapy for Nasopharyngeal Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2018, 144, 86-89.	2.2	18

#	ARTICLE	IF	CITATIONS
109	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 45-52.	1.4	18
110	Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up. <i>Annals of Surgical Oncology</i> , 2017, 24, 966-973.	1.5	17
111	Correlation between functional imaging markers derived from diffusion-weighted MRI and 18F-FDG PET/CT in esophageal cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 60-67.	1.1	17
112	Proton beam therapy for gastrointestinal cancers: past, present, and future. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 962-971.	1.4	17
113	Evolving Practice Patterns in the Use of Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e199135.	5.9	17
114	A novel deep learning model using dosimetric and clinical information for grade 4 radiotherapy-induced lymphopenia prediction. <i>Physics in Medicine and Biology</i> , 2020, 65, 035014.	3.0	17
115	Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo-radiation. <i>Redox Biology</i> , 2021, 47, 102132.	9.0	17
116	The Impact of Radiation Dose to Heart Substructures on Major Coronary Events and Patient Survival after Chemoradiation Therapy for Esophageal Cancer. <i>Cancers</i> , 2022, 14, 1304.	3.7	17
117	A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1001-1010.	1.1	16
118	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 770-777.	0.8	16
119	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. <i>Oncogene</i> , 2020, 39, 801-813.	5.9	16
120	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 28696-28710.	1.8	16
121	Design and validation of a synchrotron proton beam line for FLASH radiotherapy preclinical research experiments. <i>Medical Physics</i> , 2022, 49, 497-509.	3.0	16
122	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 100-107.	0.8	15
123	High-Flow Nasal Cannula Therapy for Exertional Dyspnea in Patients with Cancer: A Pilot Randomized Clinical Trial. <i>Oncologist</i> , 2021, 26, e1470-e1479.	3.7	15
124	Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e745-e755.	2.6	15
125	Phase II trial combining atezolizumab concurrently with chemoradiation therapy in locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8512-8512.	1.6	15
126	Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment. <i>Current Oncology Reports</i> , 2022, 24, 543-553.	4.0	15



#	ARTICLE	IF	CITATIONS
127	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. <i>JAMA Network Open</i> , 2022, 5, e2215589.	5.9	15
128	Stereotactic body radiation therapy for stage I small cell lung cancer: a single institutional case series and review of the literature. <i>Journal of Radiation Oncology</i> , 2014, 3, 285-291.	0.7	14
129	Long-term survival and toxicity outcomes of intensity modulated radiation therapy for the treatment of esophageal cancer: A large single-institutional cohort study. <i>Advances in Radiation Oncology</i> , 2017, 2, 316-324.	1.2	14
130	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, 1404-1412.e2.	0.8	14
131	Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1541-1547.	1.3	13
132	Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 274-285.	2.2	13
133	Current status and application of proton therapy for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2021, 164, 27-36.	0.6	13
134	Profiling of immune features to predict immunotherapy efficacy. <i>Innovation(China)</i> , 2021, 3, 100194.	9.1	13
135	Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer. <i>Radiotherapy and Oncology</i> , 2016, 121, 70-74.	0.6	12
136	Biological responses of human solid tumor cells to X-ray irradiation within a 1.5-Tesla magnetic field generated by a magnetic resonance imaging linear accelerator. <i>Bioelectromagnetics</i> , 2016, 37, 471-480.	1.6	12
137	Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. <i>Practical Radiation Oncology</i> , 2017, 7, 433-441.	2.1	12
138	Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies. <i>Annals of Surgical Oncology</i> , 2018, 25, 3639-3646.	1.5	12
139	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986485.	3.2	11
140	Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis. <i>Acta Oncologica</i> , 2019, 58, 1358-1365.	1.8	11
141	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	2.4	11
142	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. <i>Practical Radiation Oncology</i> , 2020, 10, 324-329.	2.1	11
143	Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients. <i>International Journal of Particle Therapy</i> , 2021, 8, 17-27.	1.8	11
144	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. <i>American Journal of Hematology</i> , 2022, 97, 411-420.	4.1	11

#	ARTICLE	IF	CITATIONS
145	Patient-Specific Lymphocyte Loss Kinetics as Biomarker of Spleen Dose in Patients Undergoing Radiation Therapy for Upper Abdominal Malignancies. <i>Advances in Radiation Oncology</i> , 2021, 6, 100545.	1.2	10
146	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.8	10
147	A Multi-Institutional Analysis of Radiation Dosimetric Predictors of Toxicity After Trimodality Therapy for Esophageal Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, e415-e425.	2.1	10
148	Implications of the Bystander and Abscopal Effects of Radiation Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 4763-4765.	7.0	9
149	Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1696-1703.	1.1	9
150	Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. <i>Advances in Radiation Oncology</i> , 2020, 5, 700-704.	1.2	9
151	Proton beam therapy for the treatment of esophageal cancer. <i>Chinese Clinical Oncology</i> , 2016, 5, 53-53.	1.2	9
152	Bayesian variable selection for a semi-competing risks model with three hazard functions. <i>Computational Statistics and Data Analysis</i> , 2017, 112, 170-185.	1.2	8
153	Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. <i>Practical Radiation Oncology</i> , 2017, 7, 63-71.	2.1	8
154	Present developments in reaching an international consensus for a model-based approach to particle beam therapy. <i>Journal of Radiation Research</i> , 2018, 59, i72-i76.	1.6	8
155	The optimal treatment approaches for stage I small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 8, 88-96.	2.8	8
156	Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. <i>Radiation Oncology</i> , 2018, 13, 258.	2.7	8
157	Hematologic variables associated with brain failure in patients with small-cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 128, 505-512.	0.6	8
158	Predicting Incomplete Resection in Non-Small Cell Lung Cancer Preoperatively: A Validated Nomogram. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1052-1058.	1.3	8
159	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. <i>Annals of Thoracic Surgery</i> , 2022, 114, 2032-2040.	1.3	8
160	Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus. <i>Advances in Radiation Oncology</i> , 2017, 2, 325-332.	1.2	7
161	p90RSK-MAG11 Module Controls Endothelial Permeability by Post-translational Modifications of MAG11 and Hippo Pathway. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 542485.	2.4	7
162	Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions. <i>Medical Physics</i> , 2021, 48, 3243-3261.	3.0	7

#	ARTICLE	IF	CITATIONS
163	Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1044-1053.	2.1	7
164	Recursive Partitioning Analysis Identifies Pretreatment Risk Groups for the Utility of Induction Chemotherapy Before Definitive Chemoradiation Therapy in Esophageal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 407-416.	0.8	6
165	Treatment disparities affect outcomes for patients with stage I esophageal cancer: a national cancer data base analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 74-84.	1.4	6
166	Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion. <i>Journal of Thoracic Disease</i> , 2020, 12, 2317-2324.	1.4	6
167	Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. <i>Radiotherapy and Oncology</i> , 2021, 163, 192-198.	0.6	6
168	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. <i>Oncotarget</i> , 2019, 10, 4703-4718.	1.8	6
169	Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 206-212.	1.7	6
170	A hybrid deep learning model for forecasting lymphocyte depletion during radiation therapy. <i>Medical Physics</i> , 2022, 49, 3507-3522.	3.0	6
171	Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. <i>Acta OncolÃ³gica</i> , 2022, 61, 403-408.	1.8	6
172	Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1â€™high locally advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8513-8513.	1.6	6
173	Hypoxia imaging in upper gastrointestinal tumors and application to radiation therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1044-1053.	1.4	5
174	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1133-1140.	1.3	5
175	Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 54-61.	1.7	5
176	High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e27-e37.	0.8	5
177	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.8	5
178	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100514.	1.7	5
179	Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. <i>Clinical Lung Cancer</i> , 2018, 19, e885-e891.	2.6	4
180	NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS7585-TPS7585.	1.6	4

#	ARTICLE	IF	CITATIONS
181	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. <i>Frontiers in Oncology</i> , 2021, 11, 748331.	2.8	4
182	The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer: A systematic review and meta-analysis. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 145-152.	1.7	4
183	Evaluating Factors for Prophylactic Feeding Tube Placement in Gastroesophageal Cancer Patients Undergoing Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 235.	2.8	3
184	Restaging after chemoradiotherapy for locally advanced esophageal cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S288-S288.	1.7	3
185	Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 665-679.	6.3	3
186	Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. <i>Clinical Lung Cancer</i> , 2022, 23, 185-190.	2.6	3
187	Exploring the Synergy of Radiative Coupling and Substrate Undercut in Arrayed Gold Nanodisks for Economical, Ultra-Sensitive Label-Free Biosensing. <i>IEEE Sensors Journal</i> , 2021, 21, 23971-23978.	4.7	3
188	The Utility of Proton Beam Therapy with Concurrent Chemotherapy for the Treatment of Esophageal Cancers. <i>Cancers</i> , 2011, 3, 4090-4101.	3.7	2
189	Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e480-e488.	2.6	2
190	Optimizing current standard of care therapy for stage III non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2033-2039.	2.8	2
191	Risk Prediction for Locoregional Recurrence in Epidermal Growth Factor Receptor-Mutant Stage III-pN2 Lung Adenocarcinoma after Complete Resection: A Multi-center Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 6114-6121.	2.5	2
192	Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 897-908.	0.8	2
193	Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. <i>Clinical Lung Cancer</i> , 2021, 22, 225-233.e7.	2.6	2
194	Analysis of PD-L1 and RAD50 in circulating cells recovered from lung cancer patients before and after induction of radiotherapy. <i>Journal of Clinical Oncology</i> , 2016, 34, e20537-e20537.	1.6	2
195	Trends and Outcomes of Proton Radiation Therapy Use for Non-small Cell Lung Cancer. <i>International Journal of Particle Therapy</i> , 2018, 5, 18-27.	1.8	2
196	National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-6.	4.9	2
197	EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4162-TPS4162.	1.6	2
198	Invited Commentary. <i>Annals of Thoracic Surgery</i> , 2013, 95, 1210-1211.	1.3	1

#	ARTICLE	IF	CITATIONS
199	Successes and Failures of Combined Modalities in Upper Gastrointestinal Malignancies: New Directions. <i>Seminars in Radiation Oncology</i> , 2016, 26, 307-319.	2.2	1
200	Is there value of tumor stromal infiltrating lymphocytes for response assessment to chemoradiation in esophageal squamous cell carcinoma?. <i>Annals of Translational Medicine</i> , 2019, 7, S283-S283.	1.7	1
201	Comparing Radiation Modalities with Trimodality Therapy Using Total Toxicity Burden. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 1001-1005.	0.8	1
202	ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2547-2547.	1.6	1
203	A multicenter study of trimodality therapy for patients 75 years and older with esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 131-131.	1.6	1
204	Active Surveillance for Medically Inoperable Stage IA Lung Cancer in the Elderly. <i>Cureus</i> , 2018, 10, e3472.	0.5	1
205	Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2020, 9, 1974-1985.	2.8	1
206	Health Care Resource Utilization for Esophageal Cancer Using Proton versus Photon Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 18-27.	1.8	1
207	Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18803-e18803.	1.6	1
208	Evaluation of dose variation to normal and critical structures for lung hypofractionated stereotactic body radiation therapy. <i>Practical Radiation Oncology</i> , 2012, 2, e15-e21.	2.1	0
209	In Reply to Song et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1311-1312.	0.8	0
210	ASO Author Reflections: Predicting Early Recurrence After Trimodality Therapy for Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 964-965.	1.5	0
211	Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 951-958.	1.2	0
212	Authors' Reply to Yajing Du's Letter to the Editor on "Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC". <i>Journal of Thoracic Oncology</i> , 2020, 15, e166-e168.	1.1	0
213	Circulating tumor DNA as a non-invasive tool to identify patients at risk for recurrence after chemoradiotherapy in stage III non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8553-8553.	1.6	0
214	In vivo imaging and quantification of oxygen tension within solid tumor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23154-e23154.	1.6	0
215	Training and validation study for sequential monitoring of CAMLs in circulation to predict ongoing progression in lung cancer patients undergoing definitive radiotherapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3053-3053.	1.6	0
216	Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11600-11600.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Nationwide shift in patterns of prophylactic cranial irradiation utilization for extensive-stage small cell lung cancer patients.. Journal of Clinical Oncology, 2019, 37, e20099-e20099.	1.6	0
218	Active Surveillance for Early Stage Lung Cancer. Clinical Lung Cancer, 2022, , .	2.6	0
219	Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Ecological Management and Restoration, 2021, , .	0.4	0
220	In Reply to Chow and Simone. International Journal of Radiation Oncology Biology Physics, 2022, 113, 236-237.	0.8	0
221	Proton beam radiotherapy for esophageal cancer: challenges and opportunities in the modern era. Precision Radiation Oncology, 0, , .	1.1	0
222	Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC.. Journal of Clinical Oncology, 2022, 40, 9061-9061.	1.6	0
223	Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic nonâ€“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055.	1.6	0
224	Monitoring PD-L1 expression on circulating stromal cells in blood predicts PFS and OS in patients with metastatic NSCLC treated with PD-L1/PD-1 immunotherapy.. Journal of Clinical Oncology, 2022, 40, 8535-8535.	1.6	0
225	Monitoring engorgement of phagocytic circulating stromal cells during chemo-radiotherapy induction predicts survival in unresectable stage 2/3 NSCLC.. Journal of Clinical Oncology, 2022, 40, 3054-3054.	1.6	0